You are viewing: Saudi Arabia Multiomics Market analysis
Part of: Multiomics Market (Global)

The Saudi Arabia Multiomics Market was valued at $14.1 Million in 2026 and projected to reach to $22.6 Million by 2031, representing a compound annual growth rate of 10.0%. Saudi Arabia's multiomics market is positioned for sustained growth as the kingdom accelerates its healthcare transformation agenda.

Saudi Arabia Multiomics Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Saudi Arabia Multiomics Market Trends and Insights

  • This growth trajectory reflects Saudi Arabia's increasing investment in advanced healthcare technologies and precision medicine initiatives aligned with Vision 2030.
  • Saudi Arabia is positioning itself as a regional hub for genomic research and personalized medicine, driving demand for integrated multiomics solutions across diagnostic and therapeutic applications. The multiomics sector in Saudi Arabia is benefiting from enhanced healthcare infrastructure, rising prevalence of chronic diseases, and government support for biotechnology innovation.
  • Saudi Arabia's healthcare sector modernization efforts and partnerships with international research institutions are accelerating the adoption of multiomics platforms.
  • By 2031, Saudi Arabia is expected to solidify its role as a key market for multiomics technologies in the GCC region, supported by growing clinical applications and increased funding for precision health initiatives..

Key Market Statistics

  • CAGR (2026-2031) 10.0% CAGR
  • Market Size, 2026 ~USD 14.1 Million
  • Forecast, 2031 ~USD 22.6 Million
  • Country Saudi Arabia

Saudi Arabia Multiomics Market Overview

Vision 2030 Alignment :

Saudi Arabia's multiomics market growth is directly supported by Vision 2030 initiatives, which prioritize healthcare modernization and precision medicine adoption across the kingdom's medical institutions.

Steady Market Expansion :

The market is projected to grow from USD 14.1 million in 2026 to USD 22.6 million by 2031, representing a 10% CAGR, demonstrating consistent investment in advanced genomic and molecular diagnostic technologies.

Healthcare Technology Investment :

Saudi Arabia is significantly increasing capital allocation toward cutting-edge multiomics platforms, genomic sequencing centers, and integrated diagnostic laboratories in major healthcare hubs.

Precision Medicine Adoption :

Growing emphasis on personalized treatment approaches and preventive healthcare is driving demand for multiomics solutions among Saudi hospitals, research centers, and pharmaceutical companies.

Saudi Arabia Multiomics Market Dynamics

  • Government support through Vision 2030 initiatives and increased funding for medical research infrastructure are creating favorable conditions for market expansion.
  • The adoption of precision medicine in clinical settings and growing partnerships between Saudi healthcare providers and international biotech firms are strengthening market fundamentals. The 10% CAGR trajectory reflects rising demand from major medical centers in Riyadh, Jeddah, and Dammam, coupled with expanding genomic research capabilities.
  • Investment in training healthcare professionals and establishing multiomics research centers will further accelerate market penetration.
  • By 2031, Saudi Arabia is expected to emerge as a regional hub for advanced diagnostic and therapeutic applications of multiomics technologies..

Market Ecosystem

logo-mobile

MULTIOMICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Provides Illumina Connected Multiomics, a cloud-based platform that integrates and analyzes genomics, transcriptomics, proteomics, epigenomics, and other multiomic datasets. For example, oncology researchers at the University of Colorado Anschutz Medical Campus used the platform to analyze proteomic data and generate insights into melanoma biology. Enables integrated analysis of multiple biological data layers, helping researchers identify biomarkers, understand disease mechanisms, and accelerate precision medicine and drug discovery. (Illumina)
company logo
Provides Chromium Single Cell Multiome ATAC + Gene Expression technology, enabling simultaneous profiling of chromatin accessibility and gene expression in individual cells. Its platforms are widely used in cancer, immunology, and developmental biology research to characterize cellular states and regulatory mechanisms. Provides a comprehensive view of gene regulation at single-cell resolution, helping researchers link regulatory elements with gene expression and identify disease-associated cell populations.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • Saudi Arabia's multiomics market is valued at USD 14.1 million in 2026 and is forecast to reach USD 22.6 million by 2031.
    • Saudi Arabia is experiencing a 10.0% CAGR, driven by Vision 2030 healthcare modernization and precision medicine adoption.
    • Saudi Arabia's government support for biotechnology and genomic research is accelerating multiomics platform deployment.
    • Saudi Arabia is emerging as a regional leader in multiomics innovation within the GCC, with expanding clinical applications.

    Multiomics Market Report Scope

    Report Metric Details
    Base Year 2026
    Fastest Growing Segment SERVICES (Offering)
    Forecast Period 2026-2031
    Growth Rate CAGR of 12.3% from 2026 to 2031
    Largest Segment PRODUCTS (Offering)
    Market Size Base Year (Billions) ~USD 3.19 (2026)
    Revenue Forecast (Billions) ~USD 5.7 (2031)
    Segments Covered Offering, Type, Technology, Method, Workflow, Application, End User

    Saudi Arabia Multiomics Market Report Segmentation

    7 segment dimensions are covered across the global market.

    By Offering

    • Products
    • Services

    By Type

    • Assay Kits & Reagents
    • Consumables
    • Instruments & Software
    • Long-Read Sequencing
    • Ms-Based Proteomics
    • Nanopore Sequencing
    • Ngs-Based Proteomics
    • Other Consumables
    • Other Proteomics Methods
    • Other Sequencing Technologies
    • Pcr-Based Proteomics
    • Smrt Sequencing

    By Technology

    • Long-Read Sequencing
    • Nanopore Sequencing
    • Other Sequencing Technologies
    • Other Technologies
    • Proteomics
    • Sequencing
    • Smrt Sequencing

    By Method

    • Chromatin Accessibility Sequencing
    • Chromatin Interaction Analysis
    • Dna Methylation Sequencing
    • Epigenomics
    • Histone Modification Profiling
    • Long-Range Sequencing
    • Long-Read & Long-Range Sequencing
    • Long-Read Sequencing
    • Ms-Based Proteomics
    • Ngs-Based Proteomics
    • Other Epigenomics Methods
    • Other Long-Read & Long-Range Sequencing Methods
    • Other Methods
    • Other Proteomics Methods
    • Other Single-Cell Omics
    • Other Spatial Omics
    • Pcr-Based Proteomics
    • Proteomics
    • Sequencing-Based Epigenomics
    • Single-Cell Epigenomics
    • Single-Cell Genomics
    • Single-Cell Omics
    • Single-Cell Proteomics
    • Single-Cell Transcriptomics
    • Spatial Epigenomics
    • Spatial Genomics
    • Spatial Omics
    • Spatial Proteomics
    • Spatial Transcriptomics

    By Workflow

    • Data Visualization & Analysis
    • Sample Preparation
    • Sequencing & Analysis/ Sample Characterization
    • Sequencing & Analysis/Sample Characterization

    By Application

    • Biomarker Discovery
    • Cell Biology
    • Clinical Diagnostics
    • Drug Discovery & Development
    • Immunology
    • Neurology
    • Oncology
    • Other Applications
    • Precision Medicine
    • Translational Research

    By End User

    • Academic & Research Institutes
    • Cros & Cdmos
    • Hospitals & Diagnostic/Clinical Laboratories
    • Pharmaceutical & Biotechnology Companies

    Target Audience

    • Healthcare Investors : Investors seeking exposure to Saudi Arabia's precision medicine sector need detailed market sizing and growth projections to evaluate investment returns and identify portfolio opportunities in the kingdom's healthcare transformation.
    • Multiomics Technology Vendors : Equipment manufacturers and software providers require Saudi Arabia-specific market data to develop localized go-to-market strategies, understand regulatory requirements, and identify key hospital and research institution customers.
    • Pharmaceutical & Biotech Companies : Drug developers and biotech firms need insights into Saudi Arabia's precision medicine adoption to plan clinical trials, establish R&D partnerships, and commercialize genomic-based therapeutics in the region.
    • Healthcare Consultants : Management consultants advising Saudi healthcare providers and government agencies require market intelligence to develop digital health strategies, technology roadmaps, and precision medicine implementation plans.
    • Research Institutions : Academic medical centers and genomic research organizations need market data to secure funding, establish collaborative networks, and position multiomics research initiatives within Saudi Arabia's healthcare ecosystem.

    Reasons to Buy this Report

    • Market Size & Growth Data : Access precise valuation figures for Saudi Arabia's multiomics market with verified 2026-2031 projections, enabling accurate financial forecasting and investment planning specific to this emerging market.
    • Vision 2030 Strategic Alignment : Understand how Saudi Arabia's national healthcare transformation agenda directly impacts multiomics adoption, helping stakeholders align product development and market entry strategies with government priorities.
    • Regional Competitive Intelligence : Gain insights into Saudi Arabia's competitive landscape, key healthcare institutions, and technology adoption patterns to identify partnership opportunities and market positioning strategies.
    • Investment & Funding Trends : Identify capital allocation patterns and government funding mechanisms supporting multiomics infrastructure development, crucial for investors and vendors planning market entry or expansion.
    • Clinical & Commercial Opportunities : Discover high-potential segments including diagnostic centers, pharmaceutical research, and hospital networks actively implementing multiomics solutions across Saudi Arabia's healthcare ecosystem.

    Frequently asked questions

    What is the current size of Saudi Arabia's multiomics market?

    Saudi Arabia's multiomics market is valued at USD 14.1 million in 2026.

    What is the projected market size for Saudi Arabia's multiomics sector by 2031?

    Saudi Arabia's multiomics market is forecast to reach USD 22.6 million by 2031.

    What is the CAGR for Saudi Arabia's multiomics market?

    Saudi Arabia's multiomics market is growing at a compound annual growth rate of 10.0% from 2026 to 2031.

    What factors are driving growth in Saudi Arabia's multiomics market?

    Saudi Arabia's multiomics market growth is driven by Vision 2030 healthcare initiatives, increased investment in precision medicine, government support for biotechnology, and rising chronic disease prevalence.

    How does Saudi Arabia's multiomics market compare to the global market?

    Saudi Arabia's 10.0% CAGR is slightly below the global average of 12.3%, reflecting regional market maturity and localized adoption patterns within the GCC region.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the current size of the multiomics market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.

    Secondary Research

    Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), European Bioinformatics Institute (EMBL-EBI), US Food and Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO), and Organisation for Economic Co-operation and Development (OECD). Omics-specific repositories and research initiatives, including Human Protein Atlas, the Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Clinical Proteomic Tumor Analysis Consortium (CPTAC), among several others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global Multiomics market, and the findings were validated through primary research.

    Primary Research

    In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

    Multiomics Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the multiomics market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    Multiomics Market : Top-Down and Bottom-Up Approach

    Multiomics Market Top Down and Bottom Up Approach

    Data Triangulation

    After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.

    Market Definition

    The multiomics market comprises commercial revenues generated from products and services used to perform integrated multiomics analyses by combining two or more molecular profiling modalities, such as genomics, epigenomics, transcriptomics, proteomics, and spatial or single-cell omics. The market includes instruments, software, assay kits, reagents, consumables, and analytical services supporting advanced multiomics workflows from sample preparation and molecular characterization to data integration, visualization, and interpretation. These technologies are used across research and clinical applications, including oncology, precision medicine, biomarker discovery, translational research, drug discovery, and clinical diagnostics, by pharmaceutical and biotechnology companies, academic and research institutions, hospitals, diagnostic laboratories, CROs, and CDMOs. The market excludes conventional single-omics technologies, routine short-read sequencing workflows, microarray-based molecular profiling, and general laboratory products not specifically designed for integrated multiomics applications.

    Key Stakeholders

    • Multiomics product & service providers
    • Multiomics bioinformatics/data analysis companies
    • Venture capitalists and other government funding organizations
    • Research and consulting firms
    • Hospitals and diagnostic clinics
    • Pharmaceutical and biotechnology companies
    • Academic and government research institutes
    • Life science companies

    Report Objectives

    • To define, describe, and forecast the multiomics market by offering, method, technology, workflow, application, end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall multiomics market
    • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC Countries (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC Countries) and the Rest of Middle East], and Africa
    • To profile the key players and analyze their market shares and core competencies
    • To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

    Available customizations:

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

    Geographical Analysis

    • Further breakdown of the Rest of Europe multiomics market, by country
    • Further breakdown of the Rest of Asia Pacific multiomics market, by country

    Company Analysis

    • Detailed analysis and profiling of additional market players (up to five)

    Segment Analysis

    • Cross-segment analysis

    Get the Full Multiomics Market Report

    Full forecast, segment splits, and company analysis for all Multiomics Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status